Show simple item record

dc.contributor.authorLevra, MG
dc.contributor.authorBenet, J
dc.contributor.authorHasan, B
dc.contributor.authorBerghmans, T
dc.contributor.authorBruni, A
dc.contributor.authorDingemans, A
dc.contributor.authorLevra, NG
dc.contributor.authorEdwards, J
dc.contributor.authorFaivre-Finn, Corinne
dc.contributor.authorGirard, N
dc.contributor.authorGobbini, E
dc.contributor.authorGreillier, L
dc.contributor.authorHendriks, L
dc.contributor.authorLantuejoul, S
dc.contributor.authorLevy, A
dc.contributor.authorNovello, S
dc.contributor.authorO'Brien, M
dc.contributor.authorReck, M
dc.contributor.authorPochesci, A
dc.contributor.authorMenis, J
dc.contributor.authorBesse, B
dc.date.accessioned2019-12-09T17:08:15Z
dc.date.available2019-12-09T17:08:15Z
dc.date.issued2019en
dc.identifier.citationLevra MG, Benet J, Hasan B, Berghmans T, Bruni A, Dingemans AM, et al. MA08.02 Durvalumab Impact in the Treatment Strategy of Stage III Non-Small Cell Lung Cancer (NSCLC): An EORTC Young Investigator Lung Cancer Group Survey. Journal of Thoracic Oncology. 2019;14(10):S277-S8.en
dc.identifier.doi10.1016/j.jtho.2019.08.557en
dc.identifier.urihttp://hdl.handle.net/10541/622537
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1016/j.jtho.2019.08.557en
dc.titleDurvalumab impact in the treatment strategy of stage III non-small cell lung cancer (NSCLC): an EORTC Young Investigator Lung Cancer Group Surveyen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentCHU Grenoble, La Tronche/FR,en
dc.identifier.journalJournal of Thoracic Oncologyen
dc.description.noteen


Files in this item

This item appears in the following Collection(s)

Show simple item record